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Frotn Ability to Measure Cell Survival
Cotne New Radiotherapeutic Strategies
by Lester J. Peters, M.D.
Professor of Radiotherapy and Head, Division of Radiotherapy
(fhis article is a brief version of Dr. Peters' chapter, ''Basic Principles
of Radiobiology in Head and Neck Oncology," in Cancer in the
Neck: Evaluation and Treatment, edited by David L. !Arson,
Alando ]. Ballantyne, and Oscar M. Guillamondegui, and to be
published this year by Macmillan.)

Cellular radiation biology was born when it became
possible to measure the effect of radiation on the viability and reproductive capacity of single cells. Since a cell's
reproductive integrity determines its ability to form a clone,
radiation biologists define cell death as loss of the cell's
clonogenic capacity.
Cell death is not always obvious immediately after radiation
exposure. Studies have shown that most cells killed by radiation
die while attempting mitosis, and this may occur after several
apparently successful cell divisions. But because the essence of
clonogenic survival is the ability to reproduce indefinitely, a
cell is considered sterilized if none of its progeny retains the
ability to reproduce. Generally, the higher the radiation dosage,
the fewer divisions will the cell accomplish before it dies.
Interphase death, a less common type of cell death from
radiation injury, occurs soon after radiation exposure and is
believed to be caused by damage to the plasma membrane. In
the head and neck region, the serous cells of the salivary glands,
but not the mucous cells, undergo interphase death after even
low radiation doses, which accounts for the acute changes in
salivary flow and composition in patients undergoing
radiotherapy.
Irradiation may also enhance apoptosis, a natural
phenomenon in which defunct or injured cells collapse into
electron-dense bodies and are ingested by adjacent parenchymal
cells.

Loss of Tissue Function
Loss of an organ's function after irradiation is the result of
depletion of the total number of functional cells, not a
decrement in function of individual cells. That is why,
depending on their kinetic and organizational status, the
functional response of tissues to radiation varies so widely.
Tissues in which cells turn over rapidly-with fast cycles of stemcell replication, maturation, and division-will show evidence

of radiation injury soon after exposure, but the rate of onset
will not be highly dose dependent. Most epithelia and the bone
marrow are in this group. Depending on the extent of stemcell depletion, these tissues may recover all their functions after
radiation.
.
Late radiation injury occurs in tissues that have slow cell
turnover-such as bone, neuroglial, and endocrine tissues-and
in differentiated parenchymal cells that may recover
reproductive function as a response to tissue loss. The extent
of delayed injury depends on radiation dosage, and its severity
tends to increase with time because of an avalanche
phenomenon in which nondividing cells that harbor latent
reproductive injury are drawn into the division cycle and
undergo mitotic death.

Dose-Response Curves
Single doses. The deposition of radiant energy is random and
discrete. Thus, cell killing by radiation approximates an
exponential function, and radiation survival curves can be
plotted on semilogarithmic coordinates, with the surviving
fraction of clone-forming cells plotted on a logarithmic scale
as a function of dose on a linear scale. On such a scale,
exponential survival is represented by a straight line whose slope
may be defined in terms of the mean lethal dose of radiation
(D0). This is the dose that would kill all cells in the population
if the dose were targeted to the critical site of each cell. But
because dose deposition is random, the mean lethal dose kills
only an average of 63% of the cells in the population targeted.
For most mammalian cells exposed to X or gamma rays, the
shape of the graph for the first
few hundred rad is not exponential but curves downward on
the semilogarithmic coordinates
(Fig. 1). The curved portion of the
survival curve, the "shoulder,"
is the region of greatest interest
to clinical radiobiologists because
it marks the dose range of conventional dose fractionation.
Fractionated doses. In fractionated radiation, the shoulder
on the survival curve reconsti- lester J. Peters. He now
continued on page 2
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tutes itself, provided that doses are separated in time by several
hours. This means that after an adequate period of recovery,
cells surviving the first dose of radiation respond to the next
doses as if they had never been irradiated. This has important
implications for hyperfractionation and accelerated
fractionation, techniques that employ more than one
radiotherapy treatment each day.
First described by Elkind and Sutton in 1959, the
phenomenon of cell recovery from nonlethal radiation injury
between doses is called ''Elkind recovery.'' A different type of
intracellular repair mechanism, but probably involving the same
enzymatic pathways, is called "potentially lethal damage repair."
This refers to the successful repair of DNA lesions by cells
allowed to rest for several hours without a stimulus to proliferate
before being assayed for survival.
Radiation characteristics. The biologic effect of a given absorbed
dose of radiation may vary markedly according to type of
radiation. We know, for example, that kilovoltage X rays are
10% to 15% more effective rad for rad than 60eo gamma rays.
Protons and high-energy electrons spread by a scanning electron
pencil beam, but not by a scattering foil, are also biologically
more effective by about the same factor.
All of these beams have low linear energy transfer (LET),
which means that the density of ionization produced by them
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Fig. 1. Example of single-dose and fractionated cell survival
curves. The single-dose curve is characterized by a shoulder
that is repeated in fractionated exposures. The figure illustrates that a surviving cell fraction of 0. 1 may be produced
by a single dose of X 1 , two doses of X 2 , five doses of X 5 , or
10 doses of X 10 . Note that because the single-dose survival curve is almost straight between O and X 10 , any further
reduction in size of dose per fraction would not significantly
increase the total dose required to produce the same surviving
fraction. (Reproduced with permission from Peters, L. J.,
and Ang, K. K.: Unconventional fractionation schemes in
radiotherapy, in V. T. Devita, Jr., S. Hellman, and S. A.
Rosenberg, eds., Important Advances in Oncology. Copyright 1986 by J. 8. Lippincott, Philadelphia.)
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is sparse. Irradiation with other particles-for example, fast
neutrons or heavy nuclei-produces tracks of dense ionization,
so that these beams are said to have high LET. High-LET beams
----i~.•
'"cG--1=~1-1-u''C~amag~~~aterial than low L ~
beams, because cells have little or no ability to repair
intracellular damage between doses of high-LET radiation.
Another difference is that cell killing by high-LET beams is less
influenced by oxygen content and cell age distribution in the
tissue.
Effect of oxygen. Hypoxic cells are more resistant to radiation
injury than well-oxygenated cells. Oxygen seems to fixate labile
radiation injury that would otherwise be repaired within
milliseconds of irradiation. Thus, although the same number
of lesions is produced by irradiation whether oxygen is present
or not, many more lesions are repaired if oxygen is absent.
January-March 1986

Dose Fractionation: The Four R's
We have known for years that the results of radiotherapy are
better when the total dosage is divided into many small
increments instead of being delivered as a single dose or in a
few large increments. The rationale for this is based on the four
R's of radiobiology.
Repair of radiation injury. When doses of low-LET radiation
are fractionated, the shoulder on the survival curve reconstitutes
itself between doses. This results in sparing from radiation injury
as a function of the size and shape of the survival curve shoulder
as illustrated in Fig. 2. Panel A shows a survival curve whose
shoulder has a steep initial slope and little curvature, whereas
the survival curve in panel B has a shallow initial slope and
more curvature. With fractionated doses of radiation, there is
much greater sparing of cells, characterized by the survival curve
of panel B. Research has shown that cells of tumors and acutely
reacting normal tissues tend to be type A and that cells of latereacting normal issues tend to be type B. Thus, dose
fractionation has a therapeutic advantage because most tumor
cells are less spared by fractionation than are late-reacting,
normal tissues.
Reoxygenation. Studies of hypoxic, radioresistant cells in solid
tumors have shown that the oxygen status of such cells improves
between dose fractions. Many reasons have been proposed for
the reoxygenation phenomenon. Whatever the mechanism, its
clinical significance is that the delivery of fractionated doses
of radiation reduces the formerly hypoxic tumor cells' chance
of surviving closely timed and repeated irradiation.
Redistribution. When radiation is given in multiple fractions,
the opportunities for irradiating a _given cell during a sensitive
phase of division are high, especially in the case of cells whose
turnover rate is fast. This is true for both acutely reacting normal
and tumor tissue, but not for late-reacting normal tissue that
has a low turnover rate. The difference enhances the possibility
of controlling the tumor and avoiding late injury to normal
tissue.
Regeneration. During courses of radiotherapy, all tissues,
normal and neoplastic, may respond to depopulation by
increasing their cell production. As with redistribution, this
mechanism is most dramatic in acutely reacting normal tissue
and tumors, in contrast to late-reacting normal tissue and
tumors whose slow turnover time is usually not affected by
- radiatioffinjury-arrd-do-es-rrot, th-erefore--;-trtgger-a1e-gerrerative
response. The regeneration mechanism is a major determinant
in deciding the best duration of radiotherapy in any given
situation. Protraction of treatment spares acute reactions but
allows regeneration. Split-course regimens do the same. In
patients in whom the regenerative potential of the tumor is
predicted to be high, accelerated fractionation is indicated.

Altered Fractionation Schedules
In the United States, the term "conventional fractionation"
generally means incremental doses of 180 to 200 cGy delivered
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RADIATION CELL SURVIVAL CURVES
Dose
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Fig. 2. Typical examples of mammalian cell survival curves
showing an initial shoulder followed by an exponential region
on semilogarithmic coordinates. Although the width of the
shoulder is the same on these two curves, the shoulder
shape is markedly different. Sparing by dose fractionation
is much greater for cells characterized by the survival curve
slope of panel B.

five days per week for six to eight weeks. Our recent attempts
to improve the therapeutic ratio have led us to administer
multiple fractions per day with two new schedules: accelerated
fractionation, in which the overall treatment time is reduced and
two daily close-to-conventional dose fractions are given, and
hyperfroctionation, in which the overall time is conventional or
slightly longer and the total dosage is increased by giving two
small dose fractions a day.
The basic principle of accelerated fractionation is to prevent
treatment failure caused by tumor cell regeneration during
treatment. Hyperfractionation, in contrast, is based on the fact
that smaller fractions increase the tolerance of late-reacting
normal tissue, thus allowing the total dosage to be higher while
increasing injury to tumor but not normal cells (Fig. 2).

Tumor Regression and Regrowth
In general, tumors with the most rapid cellular turnover rate
will respond most rapidly to radiotherapy. Those with a low cell
turnover rate wi frespond more slowly and are sometimes
mistakenly thought to be radioresistant.
After a course of radiotherapy, the prognostic significance of residual tumor depends on tumor type. Most squamous
cell carcinomas of the upper aerodigestive tract, for example,
have a moderately rapid turnover rate, so that the presence of
residual tumor at the end of radiotherapy may mean that the
tumor has not been controlled. For this reason, such a patient
will often undergo additional boosts of radiotherapy or limited

continued on page 4

3

OncoLog_ _ _ _ _ __
New Radiotherapeutic
Strategies . . .
continued from page 3
surgical procedures to remove residual disease. Conversely,
slowly proliferating tumors such as prostate cancers may show
little response at the end of treatment and yet be cured.
Different rates of tumor regression after radiotherapy make
it difficult to interpret the results of biopsies done during the
postirradiation period. Because destruction by radiation is not
usually expressed until cells attempt mitosis, histologic
examinations cannot reveal whether intact tumor cells have
retained their donogenic ability. In the absence of clinical
evidence of regrowth, biopsies of residual tumor should not,
therefore, be done. Patients with residual disease should be
closely monitored, but biopsy confirmation of recurrence should
be sought only if tumor regrowth is clinically evident.

Combinations of Radiotherapy and Surgery
The essential rationale of combining radiation and surgery
is that the two complement each other. Surgery is most effective
in removing gross tumor masses that limit radiotherapy, whereas
subclinical extensions of disease, the cause of surgical failure,
are readily treated by irradiation. Integrated treatment in many
cases offers a better prospect of cure than either modality alone.
If postoperative irradiation is necessary because of the extent
of primary disease in a patient who has no cancerous nodes in
the neck, neck dissection is not needed because any subclinical
disease will be sterilized by postoperative radiotherapy.
Conversely, for a patient whose primary tumor will be treated
by definitive radiotherapy, but in whom neck dissection is
indicated because of nodal disease, beam energies and port
arrangements should be selected with the goal of avoiding an
increase in the risk of surgical complications.

nodes. This conclusion can be traced to the fact that higher
doses of radiation could be delivered to the tongue by interstitial
techniques. Although it is undoubtedly true that tumors of
certain histologic types are more radiocurable than others, this
does not necessarily imply differences in inherent cellular
radiosensitivity as opposed to epigenetic and environmental
factors, such as the proportion of tumor stem cells, tumor cell
kinetics, and oxygen status.
Recently, Deacon et al. (Radiother Oncol 2:317-323, 1984)
collated the published data on the in vitro survival of human
tumor cell lines of diverse histologic types. The authors found
a broad correlation between surviving fraction at 200 cGy and
category of tumor ranked at five levels of perceived clinical
radiosensitivity (Fig. 3). It is clear, however, that the cellular
radiation response within each tumor category varies markedly
and that the ranges of sensitivity for the most sensitive and most
resistant clinical categories overlap. These data also demonstrate
the range of radiosensitivity of human tumor cell lines to small
doses of radiation that would be greatly magnified in a
fractionated course of treatment. Current research is aimed at
establishing assays whereby the cellular radiosensitivity of
individual patients' tumors can be measured before therapy is
begun.

1-0~

C'J

Reviewing the causes of radiation therapy failure helps us to
identify the ones that can be avoided by the best possible
application of current ideas and techniques, those not amenable
to any modification of technique, and those that are potentially
remediable b new treatment strate ies. Cancers of the head
and neck region lend themselves to evaluation of treatment
failure because they are generally easier to stage and to monitor
than tumors at other sites.
For the first half of the century, radiosensitivity was considered
to be a simple function of histologic character, and histologically
different tumor types were classified as being radiosensitive,
moderately radiosensitive, or radioresistant. Furthermore, within
the moderately radiosensitive group, differences in sensitivity
were attributed to anatomic location. Squamous carcinoma of
the mobile tongue, for example, was considered more sensitive
than squamous carcinoma metastatic to the cervical lymph
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Fig. 3. Initial slope of cell survival curve indicated by surviving fraction at 200 cGy, in
relation to clinical response
categories of A, neuroblastoma,
lymphoma, myeloma; B, medulloblastoma, small cell lung
carcinoma; C, breast, bladder,
cervical carcinoma; D, pancreatic, colorectal, squamous
lung carcinoma; E, melanoma,
osteosarcoma, glioblastoma,
renal carcinoma.

I

I

I

B C D E

Tumor volume is one of the fundamental determinants of
radiocurabili . This rind le is illustrated in Table 1 with
regard to control of cervical node metastases from squamous
carcinoma of the laryngopharynx. These data show not only
a decreasing probability of control with increasing size of lymph
node within each dosage range, but also a dose dependence for
control within each size range.
Failures of tumor control have been attributed to tumor cell
hypoxia, to tumor cell regeneration and the failure of normal
cells to redistribute, and to other causes. But the surest cause
of radiotherapy failure is geographic miss or underdosing because
of poor technique, and these must always be excluded first in
any analysis of treatment failure.
January-March 1986

Table 1. Control Rates*
as a Function of Size of Node and Radiation Dose
in Squamous Cell Carcinomas of the Laryngopharynx

Dose

~

Size

<3

cm

65 Gy

15/26 (58%)

> 65 Gy

86/95 (91 %)

~

70 Gy

> 70 Gy

3-5 cm

3/9 (33%)

> 5 cm

1/9 (11 %)

11/13 (85%) 11 /15 (73%)

Source: Bataini, J.P. et al. in J. Pineland J. Leroux-Robert,
eds., Adenopathies Cervicales Les Malignes, Masson
Publishers, Paris, 1982.

Radiotherapy Tailored
to Patient's Disease
One of the most exciting new developments in radiotherapy
is the prospect of being able to tailor treatment to the cellular
radiosensitivity of a patient's tumor. To illustrate this, Dr. Lester
J. Peters displayed a tray of cultured tumor cells collected for
a test developed in the Division of Radiotherapy.
A biopsy sample is taken from the patient's tumor, he
explained, and the tissue is broken up into single cells, which
are then placed in each well of the specially coated culture dish.
Rows of cells are irradiated with increasing doses from zero to
500 rad, and the numbers of cells that have survived and grown
in each well after two weeks of incubation are then counted
(see photo and graph).
A

*Determinate group.
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The Therapeutic Ratio
The tolerance of normal tissues within a radiation treatment
field determines the safe maximum dosage. Because the
probability of normal tissue injury is dose related, tissue tolerance
must be specified in terms of the probability of acceptable injury
in a given clinical situation. Obviously, this will vary according
to severity of complications and the gravity of the disease being
treated.
For some normal tissues-the cervical spinal cord, for
example-radiation injury is so devastating that it is totally
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Photo of cell tray (A) and graph (B) show tumor cell
survival test that enables radiologists to design treatment for
an ind ividual patient's tumor·

unacceptable, and tolerance levels are set well below the dose
"With this system we can construct a survival curve that tells
that would produce this complication. This makes it impossible
us what the effect of radiation is on that patient's tumor-to
to use radiotherapy for most tumors close to the spinal cord,
see whether it is a sensitive or relatively insensitive one. We
except for highly sophisticated particle beams that can be tightly
can test the cells with different types of radiation, with neutrons
and narrowly focused.
or X rays, and with a combination of drugs and radiation.
For less serious normal tissue injuries, tolerance will depend
"So we're getting to the point where we expect to be able
on the clinical circumstance and the philosophy of the radiation
to . predict the outcome of standard treatment and make
oncologist. Most physicians who treat patients for cancers of
appropriate modifications if they appear necessary. One such
the head and neck regard a complication rate of about 5% to
modification might be the use of hyperfractionated treatment,
10%, excluding complications !nvolving the central nervous
that is, giving two small dose fractions each day instead of the
system, as acceptable when they determine total dosage limits.
standard daily treatment.''
Using radiation treatments that are too conservative will
Since Peters came to MDAH in 1981 to head the radiotherapy
increase the number of patients in whom tumor control fails,
division, hyperfractionation protocols have been applied to
whereas excessive dose escalation will raise the proportion of
squamous cell carcinoma of the head and neck, breast, and
severe complications. The ultimate goal of all radiotherapeutic
ovaries, and other such protocols are on the way.
_ -----=__.
re-._-_s=ea=r=ch
=-=-is=-t=-=o~i=n:_::
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en-:-d---:e::-=rin::g-=-----• - --ill,-most-patients--COme-in--expecting----tO-be-treated-once--a
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tumors more suscepti e to cure by ionizing radiation or by
day, for six or seven weeks.
making normal tissues more resistant to injury.
"When we tell people that we recommend treatment twice
a
day,
they sometimes feel that's an imposition. It means they
(Physicians who desire additional information may write Lester].
have
to
spend nearly a whole day in the clinic because we require
Peters, M.D., Division of Radiotherapy, Box 97, The University
a
minimum
of four hours between treatments. We point out
of Texas M. D. Anderson Hospital and Tumor Institute at Houston,

6723 Bertner Avenue, Houston, Texas 77030.)
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continued on page 6
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Diagnosing the Rare Lesion:
Ovarian and Omental Ependymomas
lmmunocytochemical analysis was recently used by three
pathologists at MDAH to diagnose lesions, typically intracranial,
that appeared in the ovary and omentum of two patients.
According to the pathologists, fewer than 50 ependymomas have
been reported that appeared outside the central nervous system.
The ependymomas in both MDAH patients were difficult to
diagnose because of the rarity of such tumors in the abdominal
cavity.
Roupen H. Dekmezian, M.D., Nour Sneige, M.D., and Nelson
G. Ordonez, M.D., Department of Pathology, demonstrated glial
fibrillary acidic protein (GFAP) with immunohistochemical
procedures, confirming the diagnosis of ependymoma in the two
patients referred to this hospital. Ependymomas usually show
a focal and distinct staining pattern for GFAP (Fig. 1).
Histologically benign and slow growing, ependymomas are
neoplasms made up of differentiated ependymal cells, which are
usually found in the lining of brain ventricles and the spinal
cord's central canal. Although ependymomas have been
reported to occur in the sacral subcutaneous tissues, presacral
peritoneum, ovaries, mesovarium, and broad ligament, the
pathologists believe no report of an ependymoma in the omental
peritoneum exists in the literature.
The two women in whom the ependymomas were found are
both multiparous women who were in their late thirties when
they first presented with pelvic masses. Both women are alive,
one with stable disease and the other with no evidence of
disease.
In the patient in whom the omental lesion was found, two
tumor masses involving the omentum had been resected 13 years

Fig. 1. During immunohistochemical staining for GFAP, strong
reactivity is seen in the cytoplasm of tumor cells, which form
perivascular pseudorosettes.

earlier. The two tumors, one 25 cm and the other 10 cm in
greatest dimension; were removed. Her ovaries and fallopian
tubes were normal, but the physician discovered an anterior
vaginal septum, two cervices, and a uterus didelphys. A diagnosis
of malignant mesothelioma was made, and the patient
underwent a year of chemotherapy. When another pelvic mass
was discovered, she was referred to MDAH because of the
clinical impression of recurrent mesothelioma, and here the
pathological material of the previously resected tumor was

continued on page 7

Radiotherapy Tailored to Patient's Disease . . .
continued from page 5
that a course of radiothera is a once-onl treatment for an
one part of the body, and that the temporary inconvenience
is well worthwhile if it means an increased chance of cure,"
Peters said.
His department has emphasized hyperfractionated treatment
of cancers involving the larynx and hypopharynx. "F~r patients
who have advanced disease in these areas," he said, "the only
surgical option is total laryngectomy, and that has many
disadvantages beyond the patient's loss of voice and having only
a hole to breathe through. Besides the obvious psychological
and communication problems, there are problems with
showering, swimming, lifting heavy weights, and constipation.

6

"We ho e to reduce the need for la
ectomies, and our
data from the first 54 patients treated with hyperfractionated
radiotherapy look very good," Peters said.
The fresh printout on his desk showed that, so far, 42 of 54
patients treated since 1983 were completely free of disease at
the time of last follow-up. The status of two patients is unknown.
Of the 10 patients known to have relapsed, only four have
experienced recurrences at the treated site, the others having
developed metastases or other new cancers.
Peters stressed that this analysis is premature, "but the results
encourage us to continue this research initiative."

January-March 1986

continued from page 6
reviewed and diagnosed as an omental neuroectodermal tumor
with ependymal differentiation. At laparotomy multiple tumor
nodules measuring up to 10 cm in diameter were removed from
the mesentery of the small bowel and from the pelvic
peritoneum, ovaries, uterus, and liver. Surgeons performed a
total abdominal hysterectomy, bilateral salpingo-oophorectomy,
and resection of multiple peritoneal tumor nodules. Cytologic
and histologic studies confirmed the diagnosis, and
chemotherapy followed.
The second woman, who had had a right ovarian dermoid
cyst resected eight years earlier, was referred to MDAH after
laparotomy revealed and surgeons removed a large, smoothsurfaced cystic ovarian tumor with multiple tumor nodules on
the serosal surface of the uterus and in the omentum. The
patient underwent a total abdominal hysterectomy, left salpingooophorectomy, and resection of multiple tumor implants.
After a review of the pathologic material here, the lesion was
diagnosed as ependymoma of the ovary. In a second-look
laparotomy a year later following chemotherapy, microscopic
foci of residual ependymoma were found in peritoneal washings
and tissue biopsy specimens.
Sneige said the cytologic findings characteristic of
ependymoma in the peritoneal washings included numerous
isolated spindle and stellate cells having fibrillary cytoplasm and
long, tapering cytoplasmic processes, and groups of the same
type of cells forming true rosettes (Fig. 2).
Although the characteristic appearance of the individual
tumor cells and the positive staining for GFAP in isolated cells
and cell groups made the diagnosis possible, Sneige said there
were some differences in the cytologic appearance of the two
patients' tissues.
"Cell grouping varied considerably between the two cases,"
Sneige said, "though the cytomorphologic appearance of the
single cells was identical. In the patient with the ovarian
ependymoma, there were papillae, tubules, and cell clusters,
which were indistinguishable
from those seen in patients
with low-grade serous or endometrioid carcinoma, in addition
to the true rosette formation.
"Though we could find no
report in the literature linking
ovarian ependymomas with
psammoma bodies, a recent
pathology report of ependymomas in the broad . ligament Nour Sne,ge
.
noted psammoma bodies. When
we found psammoma bodies in the tissue sections and peritoneal
washings from the patient with ovarian ependymomas, we
concluded that their presence in a papillary ovarian tumor is
Vol. 31, No. 1

not pathognomonic of a Mullerian type of tumor. We knew the
true nature of the tumor from the immunoperoxidase analysis,"
Sneige said.

Fig. 2. In this peritoneal washing specimen, tumor cells are seen
in clusters forming true rosettes.

In explaining the histogenesis of ependymomas outside the
central nervous system, some scientists have advanced the
theory that the ependymomas originated in heterotopic
ependymal rests or in the coccygeal medullary vestige of the
embryonic neural tube. This theory is plausible in explaining
ependymomas that arise in the sacrococcygeal area, because
subcutaneous islands of ependymoma separated from the spinal
cord have been found in the postcoccygeal region of many
infants. The theory does not go very far, however, in explaining
the origin of ependymomas in other locations. Islands of
ependymoma are not known to exist in the female genital tract
or the omentum. According to some scientists, the neural tissue
of a teratoma after involution of other germ-layer components
or a ''unidirectional'' teratoma composed only of neural tissue
may be the origin of ependymomas in these locations.
Incomplete closure of the neural arch might enhance th~
possibility of ependymal heterotopia, and extraspinal
ependymomas have been described in several patients with spina
bifida occulta and cystica. But whether the uterine didelphys,
duplication of the cervix, and partial anterior vaginal septum
in one of these patients are associated with the ependymoma
is uncertain.
Sneige said that these two unusual cases remind cytopathologists that rare ependymal tumors may occur in unusual sites
and that immunocytochemical techniques are available to
confirm the diagnosis.

(Physicians who desire additional information may write Nour
Sneige, M.D., Department of Pathology, Box 85, The University
of Texas M. D. Anderson Hospital and Tumor Institute at Houston
6723 Bertner Avenue, Houston, Texas 77030.)
'
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Large Bowel Cancer:
Two New Books
Anthony J. Mastromarino, Ph.D., assistant vice president for
research, is an editor of two new books on cancer of the large
bowel.
Carcinoma of the Large Bowel and Its Precursors is volume 186
of Progress in Clinical and Biological Research {Alan R. Liss,
New York, 1985, $48) and the proceedings of a 1984 conference
held in Detroit. Coeditor is John R. F. lngall, M.D., of the
Department of Surgery, Wayne State University.
The conference was organized with the specific goal of
gathering ''the most useful information, of practical worth, in
the current and future attack on colorectal cancer,'' the editors
write in their foreword. Earlier detection and identification of

The book covers a wide spectrum of clinical diagnostic
techniques and includes cautious interpretations of the
applicability of animal research to clinical practice.
The other book, Large Bowel Cancer: Clinical and Basic Science
Research, volume 3 of Cancer Research Monographs {Praeger,
1985, $37.95), was coedited by Michael G. Brattain, Ph.D., of
Baylor College of Medicine.
In contrast to the clinical emphasis of the first book, this one
summarizes the status of research of large bowel disease,
stretching from the past decade's advances in fundamental
genetic and biologic knowledge to improvements in the
management of colorectal cancer. The book is drawn from a

"A singular feature ... is the interrelationship of the authors
to one another which conveys a sense of action in concert and
an anticipation of better care to come," the editors write. "The
sensitive issues of pathologically dictated radical surgery are
examined and, without question, there is anticipation that the
need for the latter ... may diminish; perhaps the colostomy
will become obsolete."
Among contributors are Gerald D. Dodd, M.D., professor and
head of the UT MDAH Division of Diagnostic Imaging, who
wrote "The Air Contrast Barium Enema-Indications and
Validity,'' a richly illustrated chapter in which he analyzes
techniques of single-contrast and double-contrast enema
examinations, stressing the greater usefulness of the latter and
explaining that colonoscopy and the double-contrast barium
enema are complementary, not competitive, diagnostic
procedures.

Project, whose headquarters were at UT MDAH, and it is
dedicated to Murray M. Copeland, M.D., the project's first
director and a former vice presi dent of this institute's University
Cancer Foundation.
MDAH staff members who
contributed to the book include Birger Jansson, Ph.D.,
and Richard G. Martin, M.D.
In addition to coediting the
volume, Mastromarino is coauthor with Sandra Wolman,
New York University Medical
Center, of the chapter on
markers of colonic cell differentiation.
Anthony J . Mastromarino
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